{"id":8666,"date":"2026-06-02T12:24:38","date_gmt":"2026-06-02T10:24:38","guid":{"rendered":"https:\/\/bioceltix.com\/?p=8666"},"modified":"2026-06-02T12:58:38","modified_gmt":"2026-06-02T10:58:38","slug":"report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company","status":"publish","type":"post","link":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/","title":{"rendered":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company"},"content":{"rendered":"

_MACHINE TRANSLATION_<\/p>\n

The Management Board of Bioceltix S.A., with its registered office in Wroc\u0142aw (the \u201cCompany\u201d<\/strong> or the \u201cIssuer\u201d<\/strong>), announces that today (i.e. on 2 June 2026) the Company received information on the submission of a request by a shareholder representing at least one-twentieth of the share capital, i.e. Towarzystwo Funduszy Inwestycyjnych PZU S.A. with its registered office in Warsaw, acting on behalf of the funds it manages (the \u201cShareholder\u201d<\/strong>), regarding the inclusion in the agenda of the Ordinary General Meeting of the Company convened for 23 June 2026 at 12:00 p.m. (the \u201cGeneral Meeting\u201d) of the following item:
\n\u2013 \u201cChanges in the Supervisory Board of the Company\u201d.<\/p>\n

The Shareholder attached draft resolutions proposed under the above-mentioned agenda item.<\/p>\n

In connection with the above, the Management Board of the Company presents below the amended agenda, in which, in accordance with the Shareholder\u2019s request, item 18 has been added to the agenda, and the previous item 18 \u201cClosing of the General Meeting.\u201d has been renumbered as item 19.<\/p>\n

Additionally, attached to this current report, the Management Board of the Issuer also provides updated documents related to the convening of the Ordinary General Meeting: the announcement of the convening, draft resolutions, and the proxy voting form.<\/p>\n

Below, the Management Board of the Issuer presents the updated agenda:<\/p>\n

    \n
  1. Opening of the General Meeting.<\/li>\n
  2. Election of the Chairperson of the General Meeting.<\/li>\n
  3. Confirmation of the correctness of convening the General Meeting and its capacity to adopt resolutions.<\/li>\n
  4. Adoption of the agenda.<\/li>\n
  5. Consideration of the Management Board\u2019s report on the activities of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  6. Consideration of the financial statements of BIOCELTIX S.A. for the financial year 2025, including the report of the independent statutory auditor on the audit of the financial statements.<\/li>\n
  7. Consideration of the Management Board\u2019s motion regarding the coverage of the loss of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  8. Consideration of the Supervisory Board\u2019s report on the activities of BIOCELTIX S.A. for the financial year 2025 and the results of the Supervisory Board\u2019s assessment of the financial statements and the Management Board\u2019s report on activities for the financial year 2025.<\/li>\n
  9. Adoption of a resolution on the approval of the Supervisory Board\u2019s report on the activities of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  10. Adoption of a resolution on the approval of the Management Board\u2019s report on the activities of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  11. Adoption of a resolution on the approval of the financial statements of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  12. Adoption of a resolution on the coverage of the loss of BIOCELTIX S.A. for the financial year 2025.<\/li>\n
  13. Adoption of resolutions on granting discharge to the members of the Management Board of BIOCELTIX S.A. for the performance of their duties in 2025.<\/li>\n
  14. Adoption of resolutions on granting discharge to the members of the Supervisory Board of BIOCELTIX S.A. for the performance of their duties in 2025.<\/li>\n
  15. Discussion on the remuneration report of the Members of the Management Board and the Supervisory Board.<\/li>\n
  16. Adoption of a resolution on establishing an Incentive Programme in the Company and repealing Resolution No. 05\/02\/2021 of the Extraordinary General Meeting of the Company dated 9 February 2021, as amended by Resolution No. 19\/06\/2024 of the Ordinary General Meeting of the Company dated 26 June 2024.<\/li>\n
  17. Adoption of a resolution on the issuance of registered subscription warrants of series A with the exclusion of pre-emptive rights of existing shareholders, conditional increase of the Company\u2019s share capital through the issuance of ordinary bearer shares of series H with the exclusion of pre-emptive rights of existing shareholders, repeal of Resolution No. 03\/02\/2021 of the Extraordinary General Meeting of the Company dated 9 February 2021 and Resolution No. 04\/02\/2021 of the Extraordinary General Meeting of the Company dated 9 February 2021, and the related amendment to the Company\u2019s Articles of Association.<\/li>\n
  18. Changes in the Supervisory Board of the Company.<\/li>\n
  19. Closing of the General Meeting.<\/li>\n<\/ol>\n

    The updated full text of the announcement convening the Ordinary General Meeting of the Company and the draft resolutions to be adopted at the Ordinary General Meeting of the Issuer are included in the attachments to this report.<\/p>\n

    Furthermore, pursuant to Article 402(3) of the Commercial Companies Code, the full text of the updated announcement convening the Ordinary General Meeting, together with attachments including updated proxy voting forms, has been published on the website:
    \nhttps:\/\/bioceltix.com\/ir\/walne-zgromadzenia\/<\/a><\/p>\n

    Detailed legal basis: Article 401 \u00a7 1 of the Commercial Companies Code.<\/p>\n

     <\/p>\n

    Attachments<\/strong><\/p>\n

    1. Announcement of convening BCX
    \n    BCX Og\u0142oszenie o zwo\u0142aniu ZWZ<\/a><\/p>\n

    2. Draft resolutions BCX
    \n    BCX Projekty uchwa\u0142 ZWZ wraz z uzasadnieniem<\/a><\/p>\n

    3. Proxy voting form BCX
    \n    BCX Fromularz g\u0142osowania przez pe\u0142nomocnika – wersja edytowalna<\/a>
    \n    BCX Fromularz g\u0142osowania przez pe\u0142nomocnika – wersja .pdf<\/a><\/p>\n

    4. Shareholder\u2019s request to extend the agenda of the General Meeting
    \n    Bioceltix_punkt porz\u0105dku obrad_zmiany w RN_ZWZ_23062026<\/a><\/p>\n

    Signatures of persons representing the Company:<\/strong><\/p>\n

    \u0141ukasz Bzdzion \u2013 Prezes Zarz\u0105du
    \nPawe\u0142 Wielgus \u2013 Cz\u0142onek Zarz\u0105du<\/p>\n

    _MACHINE TRANSLATION_<\/p>\n","protected":false},"excerpt":{"rendered":"

    _MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wroc\u0142aw (the \u201cCompany\u201d or the \u201cIssuer\u201d), announces that today (i.e. on 2 June 2026) the Company received information on the submission of a request by a shareholder representing at least one-twentieth of the share capital, i.e. Towarzystwo Funduszy Inwestycyjnych PZU S.A. with […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[],"class_list":["post-8666","post","type-post","status-publish","format-standard","hentry","category-espi-2026-en"],"yoast_head":"\nReport No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix\" \/>\n<meta property=\"og:description\" content=\"_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wroc\u0142aw (the \u201cCompany\u201d or the \u201cIssuer\u201d), announces that today (i.e. on 2 June 2026) the Company received information on the submission of a request by a shareholder representing at least one-twentieth of the share capital, i.e. Towarzystwo Funduszy Inwestycyjnych PZU S.A. with […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioceltix\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T10:24:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T10:58:38+00:00\" \/>\n<meta name=\"author\" content=\"Bioceltix\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bioceltix\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/\"},\"author\":{\"name\":\"Bioceltix\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#\\\/schema\\\/person\\\/5ab725645ee04b83368bd6929813258a\"},\"headline\":\"Report No. 13\\\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company\",\"datePublished\":\"2026-06-02T10:24:38+00:00\",\"dateModified\":\"2026-06-02T10:58:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/\"},\"wordCount\":842,\"publisher\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#organization\"},\"articleSection\":[\"ESPI 2026\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/\",\"url\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/\",\"name\":\"Report No. 13\\\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#website\"},\"datePublished\":\"2026-06-02T10:24:38+00:00\",\"dateModified\":\"2026-06-02T10:58:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Strona g\u0142\u00f3wna\",\"item\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report No. 13\\\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#website\",\"url\":\"https:\\\/\\\/bioceltix.com\\\/\",\"name\":\"Bioceltix\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bioceltix.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#organization\",\"name\":\"Bioceltix\",\"url\":\"https:\\\/\\\/bioceltix.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bioceltix.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/logo-bioceltix.png\",\"contentUrl\":\"https:\\\/\\\/bioceltix.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/logo-bioceltix.png\",\"width\":274,\"height\":73,\"caption\":\"Bioceltix\"},\"image\":{\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bioceltix.com\\\/#\\\/schema\\\/person\\\/5ab725645ee04b83368bd6929813258a\",\"name\":\"Bioceltix\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g\",\"caption\":\"Bioceltix\"},\"url\":\"https:\\\/\\\/bioceltix.com\\\/en\\\/author\\\/bioceltix\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/","og_locale":"en_US","og_type":"article","og_title":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix","og_description":"_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wroc\u0142aw (the \u201cCompany\u201d or the \u201cIssuer\u201d), announces that today (i.e. on 2 June 2026) the Company received information on the submission of a request by a shareholder representing at least one-twentieth of the share capital, i.e. Towarzystwo Funduszy Inwestycyjnych PZU S.A. with […]","og_url":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/","og_site_name":"Bioceltix","article_published_time":"2026-06-02T10:24:38+00:00","article_modified_time":"2026-06-02T10:58:38+00:00","author":"Bioceltix","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bioceltix","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/#article","isPartOf":{"@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/"},"author":{"name":"Bioceltix","@id":"https:\/\/bioceltix.com\/#\/schema\/person\/5ab725645ee04b83368bd6929813258a"},"headline":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company","datePublished":"2026-06-02T10:24:38+00:00","dateModified":"2026-06-02T10:58:38+00:00","mainEntityOfPage":{"@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/"},"wordCount":842,"publisher":{"@id":"https:\/\/bioceltix.com\/#organization"},"articleSection":["ESPI 2026"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/","url":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/","name":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company - Bioceltix","isPartOf":{"@id":"https:\/\/bioceltix.com\/#website"},"datePublished":"2026-06-02T10:24:38+00:00","dateModified":"2026-06-02T10:58:38+00:00","breadcrumb":{"@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bioceltix.com\/en\/report-no-13-2026-information-on-introducing-changes-to-the-agenda-of-the-ordinary-general-meeting-at-the-request-of-a-shareholder-of-the-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Strona g\u0142\u00f3wna","item":"https:\/\/bioceltix.com\/en\/"},{"@type":"ListItem","position":2,"name":"Report No. 13\/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company"}]},{"@type":"WebSite","@id":"https:\/\/bioceltix.com\/#website","url":"https:\/\/bioceltix.com\/","name":"Bioceltix","description":"","publisher":{"@id":"https:\/\/bioceltix.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bioceltix.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/bioceltix.com\/#organization","name":"Bioceltix","url":"https:\/\/bioceltix.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/","url":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","contentUrl":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","width":274,"height":73,"caption":"Bioceltix"},"image":{"@id":"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/bioceltix.com\/#\/schema\/person\/5ab725645ee04b83368bd6929813258a","name":"Bioceltix","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b441a3f41947338957e10d677306f0621fd7537fb2275d250f6e77a75183d336?s=96&d=mm&r=g","caption":"Bioceltix"},"url":"https:\/\/bioceltix.com\/en\/author\/bioceltix\/"}]}},"_links":{"self":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/posts\/8666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/comments?post=8666"}],"version-history":[{"count":1,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/posts\/8666\/revisions"}],"predecessor-version":[{"id":8667,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/posts\/8666\/revisions\/8667"}],"wp:attachment":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/media?parent=8666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/categories?post=8666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/tags?post=8666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}